Literature DB >> 30281035

To transfuse or not transfuse: an intensive appraisal of red blood cell transfusions in the ICU.

Margaret M Hayes1, Lynne Uhl2.   

Abstract

PURPOSE OF REVIEW: This review is a critical appraisal of the current data comparing restrictive vs. liberal transfusion strategies for patients who are critically ill in ICUs. We focus on four subsets of critically ill patients: pediatric patients, patients with gastrointestinal bleeds, septic patients and patients undergoing cardiac surgery. RECENT
FINDINGS: Almost a decade after the TRICC trial, a randomized trial showing the safety of a restrictive transfusion threshold in critically ill patients, four large randomized controlled trials have shown that a restrictive transfusion strategy is safe in pediatric critically ill patients, patients with acute upper gastrointestinal bleeds, patients with septic shock and patients undergoing cardiac surgery. A large multicenter randomized trial is underway to determine the safety of a restrictive strategy in myocardial infarction.
SUMMARY: A restrictive transfusion threshold is recommended in nearly all critically ill patients. This is at least noninferior to more liberal transfusion practice; in addition, a restrictive threshold has shown improved outcomes in some patients and decreased chances of adverse events in patients. Judicious use of red cells improves patient outcome and protects the blood supply, a limited resource. More data are needed to determine appropriate transfusion threshold recommendations for patients with traumatic brain injury and acute coronary syndrome.

Entities:  

Mesh:

Year:  2018        PMID: 30281035     DOI: 10.1097/MOH.0000000000000460

Source DB:  PubMed          Journal:  Curr Opin Hematol        ISSN: 1065-6251            Impact factor:   3.284


  1 in total

1.  Intra-operative red blood cell transfusion and mortality after cardiac surgery.

Authors:  Eline A Vlot; Lisa Verwijmeren; Ewoudt M W van de Garde; Geoffrey T L Kloppenburg; Eric P A van Dongen; Peter G Noordzij
Journal:  BMC Anesthesiol       Date:  2019-05-04       Impact factor: 2.217

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.